IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy

Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy
View Sample PDF
Author(s): Carlos Henrique Ferreira Camargo (Hospital Universitário dos Campos Gerais – UEPG, Brazil), Marcus Vinicius Della-Coletta (State University of Amazonas, Brazil), Delson José da Silva (Federal University of Goias, Brazil)and Hélio A. G. Teive (Federal University of Paraná, Brazil)
Copyright: 2019
Pages: 24
Source title: Handbook of Research on Critical Examinations of Neurodegenerative Disorders
Source Author(s)/Editor(s): Md. Sahab Uddin (Southeast University, Bangladesh)and Md. Shah Amran (University of Dhaka, Bangladesh)
DOI: 10.4018/978-1-5225-5282-6.ch013

Purchase

View Alpha-Synucleinopathies: Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy on the publisher's website for pricing and purchasing information.

Abstract

Alpha-synuclein is a protein that forms a major component of abnormal neuronal aggregates known as Lewy bodies. A particular group of neurodegenerative disorders (NDs) is characterized by the abnormal accumulation of α-synuclein; termed the α-synucleinopathies, this group includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Lysosomal storage diseases have also been linked to α-synuclein toxicity. Several therapeutic targets have been chosen among steps of metabolism of α-synuclein. Reducing α-synuclein synthesis or expression and increasing the clearance can be achieved in many ways. The development of immunotherapeutic approaches targeting α-synuclein has received considerable attention in recent years. The aim of this chapter is to present the α-synucleinopathies, as well as to present the most recent researches about treatment of synucleinopathies based on knowledge of the pathophysiology of α-synuclein pathways.

Related Content

Surinder Kaur, Gurmeet Singh. © 2025. 32 pages.
Gaganjot Kaur, Shalini Sharma, Reepu. © 2025. 18 pages.
Payal Sanan, Mohd Afjal. © 2025. 32 pages.
Pooja Mehta, Harleen Kaur. © 2025. 22 pages.
Khushi, Jaspreet Kaur, Shivani Malhan. © 2025. 18 pages.
Arabinda Bhandari. © 2025. 32 pages.
Reepu. © 2025. 22 pages.
Body Bottom